Balchem Co. (NASDAQ:BCPC) Shares Bought by Xponance Inc.

Xponance Inc. boosted its holdings in shares of Balchem Co. (NASDAQ:BCPC) by 5.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,046 shares of the basic materials company’s stock after acquiring an additional 102 shares during the period. Xponance Inc.’s holdings in Balchem were worth $315,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Envestnet Portfolio Solutions Inc. raised its position in shares of Balchem by 1.5% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 3,926 shares of the basic materials company’s stock valued at $604,000 after buying an additional 59 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Balchem by 18.0% in the first quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company’s stock valued at $73,000 after buying an additional 72 shares during the last quarter. Hsbc Holdings PLC raised its position in shares of Balchem by 1.5% in the second quarter. Hsbc Holdings PLC now owns 4,915 shares of the basic materials company’s stock valued at $757,000 after buying an additional 75 shares during the last quarter. Pitcairn Co. raised its position in shares of Balchem by 3.6% in the first quarter. Pitcairn Co. now owns 3,315 shares of the basic materials company’s stock valued at $514,000 after buying an additional 115 shares during the last quarter. Finally, Benjamin Edwards Inc. raised its position in shares of Balchem by 6.6% in the second quarter. Benjamin Edwards Inc. now owns 2,231 shares of the basic materials company’s stock valued at $344,000 after buying an additional 138 shares during the last quarter. Institutional investors and hedge funds own 87.91% of the company’s stock.

Balchem Price Performance

Balchem stock opened at $172.57 on Wednesday. Balchem Co. has a 1 year low of $110.74 and a 1 year high of $186.03. The firm has a 50 day moving average price of $171.69 and a 200 day moving average price of $160.13. The company has a market cap of $5.60 billion, a price-to-earnings ratio of 48.75, a PEG ratio of 5.54 and a beta of 0.65. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83.

Balchem (NASDAQ:BCPC) last released its earnings results on Friday, July 26th. The basic materials company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Balchem had a net margin of 12.52% and a return on equity of 10.94%. The firm had revenue of $234.08 million during the quarter, compared to the consensus estimate of $241.26 million. Sell-side analysts predict that Balchem Co. will post 3.96 earnings per share for the current year.

Insiders Place Their Bets

In other Balchem news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $180.05, for a total transaction of $1,395,387.50. Following the completion of the sale, the senior vice president now directly owns 8,540 shares in the company, valued at $1,537,627. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.25% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on BCPC shares. StockNews.com downgraded shares of Balchem from a “buy” rating to a “hold” rating in a report on Monday, July 29th. HC Wainwright boosted their target price on shares of Balchem from $170.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, July 31st.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.